Of 93 MG patients, 6 had MuSK-MG. 83% were female. 50% were Caucasian, 33.33% were African American, and 16.67% were Filipino. 66.67% had symptom onset in their 20s, 16.67% in their 30s, and 16.67% in their 40s. 

50% had initial and later respiratory dysfunction. 16.67% developed exclusively later respiratory dysfunction. 66.67% had initial and later dysarthria. None developed exclusively later dysarthria. 33.33% had initial and later dysphagia. 50% developed exclusively later dysphagia. 83.33% developed later muscle of mastication weakness, while none had this initially. 33.33% had initial and later diplopia and ptosis. 33.33% had exclusively later diplopia and ptosis. 33.33% had exclusively later neck weakness, while none had this initially. 16.67% had initial and later extremity weakness. 33.33% had exclusively later extremity weakness.

33.33% had initial MuSK titer > 1:1000 and 33.33% had Musk titer > 1:2000.

33.33% had initial bulbar crisis. 33.33% had bulbar crisis on chronic immunosuppressive therapy. 100% had non-severe bulbar dysfunction worsening while on chronic immunosuppressive therapy. 16.67% treated acutely improved with IVIG alone, 33.33% with IVIG and PLEX, and 16.67% with IVIG, PLEX, and rituximab.

None improved with pyridostigmine alone. 33.33% improved on steroids alone. 33.33% required one steroid sparing immunosuppressive drug (SSID) and 33.33% required two or more SSIDs. None were able to discontinue steroids with or without SSIDs.